Related Experiment Video

Updated: Nov 29, 2025

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations
05:04

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations

Published on: February 2, 2024

808

[Magnesium sulphate treatment decreases the risk of cerebral palsy after preterm birth]

Hanne Trap Wolf1, Tine Brink Henriksen, Mads Langager Larsen

  • 1trapwolf@gmail.com.

Ugeskrift for Laeger
|November 20, 2020
PubMed

Insights

Magnesium sulfate (MgSO4) offers neuroprotection for preterm infants, reducing the risk of cerebral palsy (CP). Evidence supports its use to prevent CP in newborns born prematurely.

Area of Science:

  • Obstetrics and Gynecology
  • Neonatology
  • Neurology

Background:

  • Preterm birth increases the risk of severe morbidity, including cerebral palsy (CP).
  • Cerebral palsy is currently untreatable, necessitating prophylactic interventions.
  • Magnesium sulfate (MgSO4) has been investigated for its neuroprotective properties in preterm infants.

Purpose of the Study:

  • To review the evidence for magnesium sulfate (MgSO4) as a neuroprotective treatment for preterm infants.
  • To determine if current evidence supports the routine use of MgSO4 for CP prevention in preterm birth.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) on MgSO4 for neuroprotection in preterm birth.
  • Inclusion of a recent RCT from Denmark.
  • Analysis of an updated meta-analysis incorporating trial sequential analysis.

Main Results:

  • Six RCTs provide data on MgSO4's efficacy in preventing CP.
  • An updated meta-analysis with trial sequential analysis confirmed a significant neuroprotective effect of MgSO4.
  • The evidence indicates a statistically significant benefit of MgSO4 treatment.

Conclusions:

  • Sufficient evidence now supports the use of MgSO4 for neuroprotection in preterm birth.
  • MgSO4 should be considered a standard prophylactic measure to prevent cerebral palsy in preterm infants.

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.6K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.6K

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
996
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
647